QTc interval prolongation and its associated factors among HIV infected patients on ART in Mettu Town Authors: Zewudu Befkadu, Betemariam Girma Published: 2024 ABSTRACT AbstractQTc interval prolongation, which is linked to cardiac arrhythmia and sudden cardiac death, is common in HIV-infected patients. This prolongation can be attributed to the side effects of antiretroviral medications, the direct impact of HIV on the heart, and chronic inflammatory responses that disrupt cardiac electrical activity. This study aimed at assessing QTc interval prolongation and associated factors among HIV-infected adults on ART. A cross-sectional study was conducted among consecutively selected 298 HIV-infected patients at Mettu Karl Specialized Hospital, southwest Ethiopia. A face-to-face interview with a structured and pretested questionnaire was employed to collect socio-demographic and behavioural characteristics data. Electrocardiography was done using a 12-lead electrocardiograph, and interpreted by a cardiologist. Data were entered into Epi-data version 4.6 and analyzed using SPSS version 25. Multivariable logistic regression analyses were done at a significance level of P < 0.05. QTc prolongation was prevalent in 12.4% of participants. Being on PIs containing HAART regimen (AOR = 5.7, 95%CI 2.54–12.8), having recent CD4 count of < 350 cells/mm3 (AOR = 4.8, 95%CI 2.19–10.5), and recent viral load of ≥ 1000coppies/ml (AOR = 2.8, 95%CI 1.24–6.42) were significantly associated with QTc prolongation. According to this study, one of the ten HIV-infected patients on ART had QTc prolongation. Therefore, we suggest that HIV-positive patients receiving treatment should undergo screening for QTc interval prolongation.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-024-79808-y.Keywords: QTc prolongation, HIV-infected patients, Mettu, EthiopiaSubject terms: Physiology, Cardiology Introduction According to the World Health Organization (WHO), in 2021, an estimated 38.4 million people worldwide were living with Human immunodeficiency virus (HIV), representing approximately 0.5% of the global population1. The prevalence of HIV disease varies widely from country to country, with sub-Saharan Africa bearing the brunt of the epidemic. In this region, an estimated 25.7 million people are living with HIV, accounting for 67% of the global total2. Ethiopia has made progress in addressing HIV/AIDS, but it still has the second-highest HIV epidemic in sub-Saharan Africa (SSA), with an estimated 609,000 people living with the virus in 20223. Advances in HIV treatment have led to a significant increase in the life expectancy of people living with HIV infection (PLWH). This, however, exposes them to an increased risk of developing chronic diseases, such as cardiovascular diseases (CVD)4–7. Studies indicated that PLWH have a higher risk of developing CVD compared to the general population, with estimates ranging from 30 to 80%. This risk is further increased in HIV-infected patients who are on antiretroviral therapy (ART)8–11. Several factors contribute to this increased risk, including the direct damage to the heart and blood vessels caused by HIV infection itself, as well as the higher prevalence of traditional CVD risk factors such as high blood pressure, diabetes, and smoking among HIV-infected patients12,13. Additionally, certain antiretroviral drugs can also increase the risk of CVD13. QT interval prolongation, which can be monitored by simple electrocardiogram (ECG), is common in HIV-infected patients. To accurately interpret QT interval, it should undergo rate correction (QTc) to account for variations in heart rate. The prevalence of QTc interval prolongation in HIV-infected patients on ART is estimated to be between 9 and 29%14–20. QTc interval prolongation can increase the risk of developing potentially life-threatening arrhythmias, such as torsades de pointes that can lead to sudden cardiac death (SCD)21. The SCD risk is estimated to be 2.2-fold increased in patients with a prolonged QTc22,23. QTc interval prolongation in HIV-infected patients can be attributed to several factors. Some ART medications, such as protease inhibitors (PIs), can slow down the electrical activity of the heart and prolong the QT interval. Studies showed that PIs causes QTc prolongation by inhibiting rapidly activating delayed rectifier potassium current (IKr) in cardiac tissues, which is conveyed by the human ether-a-go-go-related gene (hERG)-encoded voltage dependent potassium channel19,24,25. In addition, it was also reported that HIV Tat protein inhibits IKr through the inhibition of hERG protein expression, which might be the potential mechanism of HIV infection induced QTc interval prolongation26,27. On the other hand, there is growing evidence that chronic inflammation due to HIV infection and opportunistic infections can contribute to disturbances in cardiac electrical activity, which is correlated with a lower CD4 count4,28,29. Studies conducted in Thailand, Italy and Lebanon have revealed an association between decreased CD4 cell counts in individuals with HIV and an elevated risk of QT interval prolongation30–32. The manifestations of HIV infection in organs other than the heart may mask the clinical evidence of cardiac disease in HIV-infected subjects33. However, electrocardiography (ECG) can be a convenient screening tool, especially in resource-limited settings. Ethiopia is one of the SSA countries sharing the high burden of HIV-related morbidity and mortality. In this country, limited studies have been conducted to identify the prevalence of cardiovascular risk factors in HIV-infected individuals. Currently, there is no available published data on QTc interval prolongation and factors associated with having prolonged QTc among HIV-infected patients in this country. So, this study aimed at assessing QTc interval prolongation and associated factors among HIV-infected adults on ART at Mettu Karl Specialized Hospital ART clinic. Materials and methods Study setting and design A hospital-based cross-sectional study was conducted at Mettu Karl Specialized Hospital, which is located in Mettu Town, 600 km away from Addis Ababa, the capital city of Ethiopia to the southwest. This hospital serves about 2.5 million people from different regions of the country. The hospital’s health service covers the outpatient department, inpatient services, critical care, emergency intervention unit, and different clinics, such as antenatal care clinics, delivery services, tuberculosis clinics, ART clinics, and ophthalmology clinics. Currently, about 1596 HIV-infected adult clients are taking a different combination of ART drugs at this hospital. The study was conducted from November 4 to December 25, 2022. Study population All HIV-infected patients aged ≥ 18 years and on follow-up in ART clinic, who were on ART for at least 6 months, and had a complete clinical profile during the data collection were included in the study. Pregnant women and women in the postpartum period, patients taking drugs that have a direct effect on the cardiovascular system (except for ART drugs), severely ill patients who cannot respond or perform our study procedure, patients who have been diagnosed with congenital or acquired heart disease, systemic hypertension, chronic respiratory diseases, diabetic Mellitus and chronic kidney disease were excluded from the study. Sample size determination and sampling technique The sample size was determined using the single population proportion formula for a cross-sectional study: n = Z2 pq/d2. In this formula, Z represents a two-sided confidence level of 95%, which is 1.96; p is the estimated prevalence of QTc prolongation among HIV-infected adults on ART, set at 0.5 due to a lack of prior published data in Ethiopia; and d is the margin of error, specified as 5% or 0.05. Given these parameters, the sample size was calculated as follows: n = (1.96)2(0.5*0.5)/ (0.05)2, resulting in an initial sample size of 384. Since the source population is less than 10,000, we applied the sample size correction formula: nf = no/(1 + (no-1)/N), where N = 1596 and no = 384. This adjustment yielded a final sample size of 310. Participants who met the inclusion criteria and visited the hospital ART clinic during the study period were consecutively enrolled until the required sample size was reached. Data collection procedures Data on socio-demographic and behavioral characteristics were collected using semi-structured, interviewer-administered questionnaires. These questionnaires were specifically designed for this study by one of the authors, Mrs. Betemariam Girma. Data such as the duration of HIV disease since diagnosis, ART duration and regimen, recent viral load, recent CD4 count, and WHO clinical stage of HIV infection were obtained from the patient’s medical record. Height was measured with a stadiometer to the nearest centimeter without shoes. Weight was measured with a weighing scale (Seca gmbh & co. kg. Germany) and recorded to the nearest 0.1Kg. Body mass index (BMI) was calculated by the formula: observed weight in Kg divided by squared height in meter (Kg/m2). Blood pressure was measured using a mercury sphygmomanometer and recorded to the nearest mmHg. Electrocardiography A resting 12-lead body surface electrocardiography was performed using EDAN SE-1200Express electrocardiograph machine for each study participant. The ECG record was taken at standardization of 1mv = 10 mm and paper speed of 25 mm/sec from each study participant as per standard guidelines for at rest ECG recording. All metallic ornaments and clothing from the waist up were removed from each participant by ensuring privacy. The skin was prepared for the electrode placement by shaving hair, rubbing with alcohols swabs and the area dried with gauze pads. The cardiac gel was applied to electrode placement areas and the electrodes were applied on the ankle of lower legs, wrist of forearms, and pericardial area. The ECG record was taken in quit room and the participant was advised to breathe normally, relax, be comfortable, calm, and close his/her eyes during the recording time. The printed ECG record was reviewed and interpreted by a cardiologist. The QT interval was determined as the duration from the onset of the Q wave to the termination of the T wave, measured in lead II across a 10-second ECG tracing. The maximum QT interval observed among multiple consecutive measurements was recorded. In cases where a prominent U wave merged with the T wave, it was incorporated into the measurement. The QTc was calculated by using Bazzet’s formula, which is QTc = QT/√RR34. The RR interval was calculated as the time elapsed between successive R waves. For irregular heart rhythms, the average of three consecutive RR intervals was utilized. Study variables Dependent variables QTc prolongation. Independent variables age, sex, educational status, marital status, occupation, residence, alcohol use, smoking, chewing khat, physical activity, weight, height, and BMI, blood pressure, duration on ART, ART regimen, duration of HIV infection since diagnosis, CD4 count, viral load and WHO clinical stage. Operational definitions Prolonged QTc: defined as a QTc value ≥ 450 ms in males and ≥ 460 ms in females35. Prolonged QTc: defined as a QTc value ≥ 450 ms in males and ≥ 460 ms in females35. Smoker: Participants who had history of ever smoking or currently smoking. Smoker: Participants who had history of ever smoking or currently smoking. Ever smoker: Refers to individuals who had smoked for more than six months in their life time. Ever smoker: Refers to individuals who had smoked for more than six months in their life time. Current smoker: Refers to the active smoking of one or more manufactured or hand-rolled tobacco cigarettes on one or more days within one month prior to the study. Current smoker: Refers to the active smoking of one or more manufactured or hand-rolled tobacco cigarettes on one or more days within one month prior to the study. Physical activity: Any body movement produced by skeletal muscles causing energy expenditure36. Physical activity: Any body movement produced by skeletal muscles causing energy expenditure36. Physically inactive: Any vigorous physical activity < 75 min or moderate physical activity < 150 min per week36. Physically inactive: Any vigorous physical activity < 75 min or moderate physical activity < 150 min per week36. Physically active: Any vigorous physical activities ≥ 75 min or moderate physical activities ≥ 150 min per week36. Physically active: Any vigorous physical activities ≥ 75 min or moderate physical activities ≥ 150 min per week36. Recent CD4 count: CD4 count conducted within the last 6 months prior to data collection. Recent CD4 count: CD4 count conducted within the last 6 months prior to data collection. Recent viral load: viral load test performed within the last year prior to data collection. Recent viral load: viral load test performed within the last year prior to data collection. Data quality control To assure data quality, the questionnaires were prepared in English and translated into Afan Oromo and Amharic, then translated back to English by another person to check for consistency. Pre-testing of the questionnaires was performed using 5% of the sample size at Bedelle Hospital before the actual data collection to ensure clarity, understandability, consistency, and accuracy of the questionnaires. The training was given to the data collectors and supervisors on how to collect the data to maintain the reproducibility. All equipment were calibrated before each measurement. Interpretation of the electrocardiogram was done by a cardiologist. Data processing and analysis After cleaning and coding, the data was entered into Epi-data version 4.6.0.4 and exported to SPSS version 25.0 for analysis. The exported data was then carefully examined to identify any outliers or missing values. Descriptive statistics were calculated to summarize the variables and provide a comprehensive overview of the data. Continuous variables were expressed as mean ± standard deviation, while categorical variables were presented in terms of frequency and percentage distributions. For variables that did not follow a normal distribution, the median with interquartile range (IQR) was reported to indicate dispersion. Binary logistic regression analysis was done to identify significant predictors of QTc prolongation. Variables with a P-value < 0.25 in simple binary logistic regression were considered as candidates for inclusion in the multivariable logistic regression analysis, and variables with a p-value < 0.05 were declared as statistically significant in the final model. The degree of association between dependent and independent variables was explained using an odds ratio with a 95% confidence interval. The adequacy of the final model in predicting the outcome variable was checked by the Hosmer-Lemeshow goodness-of-fit test. Ethical approval and consent This study was conducted after ethical clearance and approval were obtained from the Ethical Review Committee of Collage of Health Sciences, Mattu University. The procedures and measurements done in this research were carried out in adherence to established guidelines and regulations, specifically Declaration of Helsinki37. Each study participant was briefed on the objectives and procedures of the study. Thereafter, informed written consent was obtained from those volunteers to participate in the study. The study participants were assured that their responses and any information obtained from the study would be kept confidential. The ECG recording was done in a private room, and a unique coding system was used for identification. Individuals with abnormal ECG findings during the study period were informed to visit the cardiology clinic for further investigation and management. All equipment were cleaned before being used on subsequent study participants. Results Socio-demographic characteristics of the participants A total of 310 HIV-infected patients on HAART were interviewed and underwent electrocardiography. However, the ECG records of 12 participants were not considered in the analysis due to their poor quality. Therefore, the data analysis included a total of 298 study participants. The mean age of study participants was 37.6 ± 9.1 years, with a minimum age of 21 and a maximum of 61 years. Out of the total participants, 187 (62.8%) were female, 143 (48%) were married, 233 (78.2%) lived in urban areas, 34 (11.4%) had not received formal education, and 87 (29.2%) were employed (Table 1). Table 1Socio-Demographic, behavioral and physical characteristics of study participants.Socio-demographic, behavioral and physical characteristicsTotalNormal QTcProlonged QTcN%n%n%SexMale11137.29431.5175.7Female18762.816756206.7Age groupLess than 4016655.714849.718640–5911939.910033.6196.460 and above134.4134.3600ResidenceRural6521.85819.572.3Urban23378.220368.13010Marital statusSingle3010.1237.7272.3Married14348.012943.3144.7Divorced8428.27224.2124Widowed4113.83712.441.3Educational statusNo formal education3411.4299.7351.7Primary9130.57625.5155Secondary10334.69531.982.7Collage and above7023.56120.593OccupationFarmer3913.1268.72134.4Housewife7324.56220.8113.7Merchant3712.43411.431Employed8729.28628.910.3Daily labourer4314.43812.851.7*Other196.4155.0341.3Smoking statusNon smoker25786.223077.2279Smoker4113.83110.4103.4Alcohol consumptionNo25886.622876.53010.1Yes4013.43311.172.3Physical activityActive15150.713645.6155.1Inactive14749.312543227.3BMI< 18.5 kg/m2299.73237.7262.0118.5–24.99 kg/m222073.819665.8248.0525–29.99 kg/m23712.43311.141.34≥ 30 kg/m2124.0393.0231.01Other- Private, Students, female sex workers, no specified job. Socio-Demographic, behavioral and physical characteristics of study participants. Other- Private, Students, female sex workers, no specified job. Behavioural characteristics and physical parameters of participants The study revealed that 41 (13.8%) of the participants were smokers. Additionally, 40 (13.4%) reported drinking alcohol, while 17 (5.7%) reported chewing khat. Almost half of the respondents (49.3%) were categorized as physically inactive (Table 1). In terms of physical measurements, the average weight of participants was 61.45 ± 11.16 kg, and their average height was 1.66 ± 0.05 m. The mean BMI of the participants was 22.23 ± 3.53 kg/m2. The average diastolic blood pressure among participants was 73.62 ± 6.72 mmHg, while the average systolic blood pressure was 112.55 ± 9.60 mmHg. Clinical characteristics of study participants The median years of HIV infection since diagnosis was 12 (IQR = 6) with minimum of 1 year and maximum of 18 years. The median years of duration on ART was 9 (IQR = 5) with minimum of 1 year and maximum of 16 years, and 53 (17.8%) of them were using PIs containing ART regimens. The median duration of HIV infection since diagnosis was 12 years (IQR = 6), ranging from a minimum of 1 year to a maximum of 18 years. The median duration on ART was 9 years (IQR = 5), with a minimum of 1 year and a maximum of 16 years. Additionally, 53 participants (17.8%) were on ART regimens that included PIs. Among the participants, 46 (15.4%) had a recent viral load of ≥ 1000 copies/ml, 252 (84.6%) had a viral load of < 1000 copies/ml, and 204 (68.4%) had an undetectable viral load. Additionally, 92 (30.9%) had a recent CD4 count of < 350 cells/mm3, and 34 (11.4%) were classified under WHO clinical stage four (Table 2). Table 2Clinical characteristics of the participants.ParametersTotalNormal QTcProlonged QTcn%n%n%Recent viral load< 1000 copies/ml25284.622876.5248.05≥ 1000 copies/ml4615.43311.1134.36Recent CD4 count< 350 cells/mm39230.96923.2237.72≥ 350 cells/mm320669.119264.4144.7Duration of HIV infection since diagnosis< 5 years4414.83612.182.685–9 years5217.44013.4124.03≥ 10 years20267.818562.1175.7Duration on ART< 5 years7123.86722.541.345–9 years9732.68628.9113.69≥ 10 years13043.610836.2227.38ART regimenPI containing5317.83712.4165.37Non-PI containing24582.222475.2217.05WHO clinical stageStage 113946.61314482.68Stage 26822.85618.8124.03Stage 35719.14816.193.02Stage 43411.4268.7282.68ART- Anti retroviral therapy; PI- Protease inhibitors. Clinical characteristics of the participants. ART- Anti retroviral therapy; PI- Protease inhibitors. Electrocardiogram characteristics of participants All participants had heart rates within the normal range, with a mean heart rate of 78.4 (± 11.2) beats per minute. The findings related to the QT interval were documented in Table 3. Table 3QT interval of participants.Major ECG findingsHeart rate, mean (SD)78.4 (11.2)QT in milliseconds, mean (SD)376.3 (23.4)QTc in milliseconds, mean (SD)426.2 (24.2)QTc Normal QTc261 (87.6) Prolonged QTc, n (%)37 (12.4) QT interval of participants. Factors associated with QTc prolongation In bivariable logistic regression, variables like sex, smoking status, physical activity status, duration on ART, ART regimen, recent viral load, and recent CD4 level were associated with QTc prolongation at a P-value of < 0.25. Multivariable logistic regression using backward LR was done to identify the best predictors of QTc prolongation after checking for collinearity of independent variables by running pseudo-linear regression. The adequacy of the final model in predicting the outcome variable was demonstrated by a non-significant chi-square statistic of 0.796 (> 0.05) obtained from the Hosmer-Lemeshow goodness-of-fit test at the last step of the regression analysis (Supplementary Table 1). Accordingly, being on PIs containing ART regimen (AOR = 5.7, 95%CI 2.54–12.8), having recent CD4 count of < 350 cells/mm3 (AOR = 4.8, 95%CI 2.19–10.5), and recent viral load of ≥ 1000coppies/ml (AOR = 2.8, 95%CI 1.24–6.42) were significantly associated with QTc prolongation (Table 4). Table 4Bivariable and multivariable logistic analysis of factors associated with QTc prolongation.Variable categoryQTc prolongationBivariable analysisMultivariable analysisYes, n (%)No, n (%)COR [95% CI]P valueAOR [95% CI]P valueSex Female20 (6.7)167 (56.0)10.24510.109 Male17 (5.7)94 (31.5)1.5 [0.75–3.02]1.9 [0.86–4.35]Smoking status Non-smoker27(9.0)230 (77.2)10.15010.464 Smoker10 (3.4)31 (10.4)2.7 [1.21–6.22]1.5 [0.51–4.30]Physical activity Active15 (5.0)136 (45.6)10.19010.752 Inactive22 (7.4)125 (42.0)1.6 [0.79–3.21]0.8 [0.36–2.05]Duration on HAART < 5 yrs.4 (1.3)67 (22.5)11 5–9 yrs.11 (3.7)86 (28.8)2.1 [0.65–7.02]0.2101.3 [0.37–4.69]0.670 ≥ 10 yrs.22 (7.4)108 (36.2)3.4 [1.13–10.3]0.003*2.0 [0.61–6.66]0.248HAART regimen Non-PI containing21 (7.0)224 (75.2)10.000*10.000* PI containing16 (5.4)37 (12.4)4.6 [2.20–9.64]5.7 [2.54–12.8]Recent viral load < 1000 copies/ml24 (8.0)228 (76.5)10.001*10.013* ≥ 1000 copies/ml13 (4.4)33 (11.1)3.7 [1.74–8.06]2.8 [1.24–6.42]Recent CD4 level ≥350 cells/mm314 (4.7)192 (64.4)10.000*10.000* <350 cells/mm323 (7.7)69 (23.2)4.5 [2.23–9.38]4.8 [2.19–10.5]*Statistically significant; COR- Crude odds ratio; AOR- Adjusted odds ratio; CI- Confidence interval; HAART- Highly active antiretroviral therapy; PI- Protease inhibitors. Bivariable and multivariable logistic analysis of factors associated with QTc prolongation. *Statistically significant; COR- Crude odds ratio; AOR- Adjusted odds ratio; CI- Confidence interval; HAART- Highly active antiretroviral therapy; PI- Protease inhibitors. Discussion This study found that the prevalence of prolonged QTc was 12.4% among the HIV-infected population on ART at MKSH. This finding is in line with studies done in South Africa (8.7%)20, Italy (9.8%)19 and Denmark (9%)14. However, it is lower than the reported rates from studies conducted in Germany (22.8%)15, USA (28.9%)16 and Nigeria (28%)18. In contrast, it was higher than that of a study done in Kenya (3.5%)38. The variation in prevalence could be due to the inclusion of patients with multiple co-morbidities and co-medications that can contribute to QTc prolongation, which were excluded in this study. Additionally, the use of different cutoff points to define QTc prolongation may also contribute to discrepancies in prevalence rates. Several factors have been associated with QTc prolongation in HIV-infected patients receiving ART. This study found that using PIs containing ART regimen is significantly associated with QTc prolongation after adjusting for other independent variables. Patients taking PIs containing HAART were found to be more than five times more likely to have prolonged QTc. This finding is supported by studies in Italy19 and China25. Several studies have recognized a pathophysiologic link between PIs and QTc prolongation. It is shown that PIs such as lopinavir, nelfinavir, ritonavir, and saquinavir cause a dose-dependent block of HERG-K + potassium channels prolonging total time for complete repolarization24. In this study, a lower CD4 count was found to be significantly associated with QTc prolongation. This finding aligns with previous research conducted in Thailand30, Italy31, and Lebanon32, which similarly reported a significant association between reduced CD4 cell counts and prolonged QT intervals. Prior investigations have established a robust correlation between CD4 cell count and cardiovascular disease, indicating that lower CD4 counts are associated with an elevated risk of cardiovascular events28. One potential explanation for this relationship is that HIV infection induces chronic inflammation, with a lower CD4 count serving as an indicator of compromised immune function29. Although the current study did not evaluate inflammatory cytokines due to budgetary limitations, existing evidence suggests that inflammatory cytokines, particularly tumor necrosis factor (TNF)-α, interleukin‐1, and interleukin‐6, can modulate ion channel function39,40. Research involving patients with rheumatoid arthritis has also demonstrated a significant association between QT interval prolongation and inflammatory markers, including C-reactive protein (CRP), TNF-α, and various interleukins (IL-1α, IL-1β, IL-6)41. This inflammatory response may directly or indirectly influence the electrical activity of the heart, thereby contributing to QTc prolongation. Furthermore, studies conducted in animal models have shown that inflammatory markers, specifically TNF-α, can diminish the hERG current in HEK 293 cells expressing hERG in a concentration-dependent manner. This mechanism may elucidate how inflammatory cytokines contribute to QTc prolongation42. This study also found a significant association between the lengthening of QTc interval and the current viral load of the participants. Individuals with a viral load exceeding 1000 copies/mm3 were almost three times more likely to have a prolonged QTc interval. This correlation could be attributed to various mechanisms. HIV has the ability to directly infect the myocardial wall, which can disrupt the electrical activity of the heart43. Furthermore, studies have shown that the HIV Tat protein can inhibit IKr by suppressing the expression of hERG protein. This inhibition may be a potential mechanism for the prolongation of QTc interval caused by HIV infection27. An experimental study conducted in China on animals demonstrated that the HIV Tat protein had a significant inhibitory effect on hERG K + channels. This resulted in a reduction of IKr currents and a prolongation of action potential duration in guinea pig cardiomyocytes26. The final model of logistic regression analysis indicated no significant association between smoking and QTc prolongation in this study, which contrasts with findings from previous research conducted in Denmark14 and Germany15. This difference may be due to the lower prevalence of smoking among participants in the current investigation. Limitation of the study We employed Bazett’s correction formula for QT interval adjustment, which is known to underestimate QTc at lower heart rates and overestimate it at higher heart rates. Sensitivity analyses to address these limitations were not conducted in this study. Additionally, the study lacked quality control measures for QT interval estimation, relying on a single ECG tracing for analysis. Furthermore, we were unable to assess the electrolyte status and cardiac inflammatory markers, such as C-reactive protein, Interleukin-6, Tumor Necrosis Factor-alpha, Interleukin-1 beta, and Nuclear Factor Kappa B due to budgetary constraints. Conclusion and recommendation The present study revealed that one of the ten HIV-infected participants on ART had QTc prolongation. Being on PIs containing ART regimen, a decline in CD4 count and having a viral load above 1000 copies/mL were identified as significant predictors of QTc prolongation. Therefore, we suggest that HIV-positive patients receiving treatment should undergo screening for QTc interval prolongation, with particular attention given to those taking ART regimens containing PIs, individuals with a lower CD4 counts, and those with a higher viral load. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Abbreviations Antiretroviral therapy Cardiovascular diseases Electrocardiography human ether-a-go-go-related gene Mettu Karl Specialized Hospital Protease inhibitors People living with HIV infection Heart rate corrected QT interval Sudden cardiac death Sub-Saharan Africa World Health Organization Author contributions Z.B. conceived the idea, analyzed the data, and wrote the draft of the manuscript. B.G. was involved in preparing the data collection tools and supervised the data collection. All authors reviewed and approved the final draft of the manuscript. Funding The authors received no financial support for this study and the study was funded by the authors. Data availability The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.